Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response.

Chronic inducible urticaria (CIndU) is characterized by wheals, angioedema or both in response to specific and definite triggers[1] . Half of CIndU patients are refractory to H1 -antihistamine treatment even at higher doses[2] . Multiple studies have proven the benefits of omalizumab in chronic spontaneous urticaria[3] . Real life data on the efficacy and safety of omalizumab treatment in CIndU are limited[4, 5] .